Cara Therapeutics - Outbreak or Selloff?
Cara Therapeutics is back on the strong resistance line that has been tested 4 times. Only once, in June 2017, was this briefly broken after FDA breakthrough therapy designation.
CR845 reduces itching in patients with chronic liver insufficiency. This brought in June 2018 3 large pharmaceutical companies on the plan, who wanted to market this product against once and milestone payments.
Outlook:
To confirm the breakout, a week-end above the blue resistance line is necessary. Following this, a retest of this resistance would be ideal to confirm this as a support zone.
If share price can not establish a weekly close above, is to expect a subsequent sale.
greeting
Stefan Bode
CR845 reduces itching in patients with chronic liver insufficiency. This brought in June 2018 3 large pharmaceutical companies on the plan, who wanted to market this product against once and milestone payments.
Outlook:
To confirm the breakout, a week-end above the blue resistance line is necessary. Following this, a retest of this resistance would be ideal to confirm this as a support zone.
If share price can not establish a weekly close above, is to expect a subsequent sale.
greeting
Stefan Bode
t.me/stefan_bode_analysen
Zins oder Dividende? Aktien oder Anleihen? Was sind Wandeloptionsanleihen?
Immobilien oder Rohstoffe?
Rinderfarm in Südamerika.
Geld richtig investieren!
fondslounge.de
Zins oder Dividende? Aktien oder Anleihen? Was sind Wandeloptionsanleihen?
Immobilien oder Rohstoffe?
Rinderfarm in Südamerika.
Geld richtig investieren!
fondslounge.de
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.